Opus Genetics Highlights Multi‑Asset Pipeline With 2026 Data Readouts, Ophthalmic Gene Therapy Trials, sNDA For Presbyopia, And JPM Healthcare Conference Presentation

- Multi-asset pipeline with significant targeted data readouts and milestones -

- Two lead ophthalmic gene therapy programs in clinical trials with new data anticipated in 2026 -

- Supplemental New Drug Application (sNDA) submitted for partnered presbyopia treatment -

- Corporate presentation at J.P. Morgan Healthcare Conference on Thursday, January 15, at 8:15 a.m. PT -

RESEARCH TRIANGLE PARK, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) (the "Company," "Opus," or "Opus Genetics"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today highlighted its progress achieved during 2025 and upcoming catalysts in 2026.

In 2026, Opus is expected to announce clinical data from its BEST1 program and accelerate its LCA5 program into pivotal testing and toward potential U.S. Food and Drug Administration (FDA) approval. Additional programs are also expected to advance into the clinic. Most of Opus' pipeline programs have the potential to qualify for Rare Pediatric Disease designation, which could result in Priority Review Vouchers (PRV), providing future non-dilutive capital.